International immunopharmacology
Cure8 research brief
Why This Matters
Preclinical evidence that a natural compound (Fraxin) can reduce epithelial necrosis and inflammation in UC models points to a potential new target (P2Y14R/cAMP/PKA/CREB) for future drug research and possibly novel therapies.
Who Should Pay Attention
Researchers studying UC mechanisms, translational drug-discovery teams, and clinicians interested in emerging basic-science findings about epithelial barrier protection in UC.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This is an experimental preclinical study using mice and HT-29 cells, not a clinical trial in people. The authors used molecular docking and cellular thermal shift assays to support binding between Fraxin and P2Y14R, and they tested pathway effects with overexpression and protein assays.
The work suggests a possible mechanism by which a natural compound might protect colonic epithelial cells and reduce inflammatory cascades in UC, which could inform future drug-discovery or translational research. Because this is an abstract-level summary of a laboratory study, it does not provide evidence that Fraxin is safe or effective in people with UC.
Keep In Mind
This article is an abstract-level summary of laboratory work (mouse and cell models). It does not report clinical safety or efficacy in humans and should not be interpreted as medical advice. Further preclinical replication and clinical testing would be required before patient use.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationInternational immunopharmacology
AuthorsZhiwei Miao, Bo Chen, Shu Bu +4 more
InstitutionZhangjiagang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, China.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedOct 16, 2026, 12:00 AM
Content availableJournal abstract
Conflict statement: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Celastrol ameliorates ulcerative colitis by inhibiting HSP90-mediated necroptosis of intestinal epithelial cells
The study suggests a new mechanism—blocking HSP90-mediated necroptosis of intestinal epithelial cells—that may reduce inflammation and tissue damage in ulcerative colitis, which could guide early drug-discovery efforts.
A sesterterpenoid derivative alleviates ulcerative colitis through targeting ProRS to suppress the NLRP3 inflammasome
A new small molecule that blocks the NLRP3 inflammasome via ProRS could point to future drug strategies for ulcerative colitis — a pathway involved in intestinal inflammation that matters to people with IBD. This is...
Coixol attenuates Ulcerative Colitis by modulating the ILC3 response via the Wnt/β-catenin pathway.
This study identifies a plant-derived compound that reduced inflammation and promoted intestinal healing in mouse models by modulating the Wnt/β-catenin pathway and ILC3-driven IL-22 production—pathways relevant to...